nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABL1—Parkinson's disease	0.597	1	CbGaD
Vandetanib—Afatinib—ABL1—Parkinson's disease	0.00196	0.214	CrCbGaD
Vandetanib—Bosutinib—MERTK—Parkinson's disease	0.00182	0.199	CrCbGaD
Vandetanib—Bosutinib—LRRK2—Parkinson's disease	0.00162	0.177	CrCbGaD
Vandetanib—Erlotinib—ABL1—Parkinson's disease	0.00139	0.151	CrCbGaD
Vandetanib—EPHA5—forebrain—Parkinson's disease	0.00116	0.00749	CbGeAlD
Vandetanib—MAP2K5—hindbrain—Parkinson's disease	0.00106	0.00688	CbGeAlD
Vandetanib—FLT4—embryo—Parkinson's disease	0.00101	0.00654	CbGeAlD
Vandetanib—STK35—brainstem—Parkinson's disease	0.000997	0.00647	CbGeAlD
Vandetanib—ERBB3—embryo—Parkinson's disease	0.00096	0.00623	CbGeAlD
Vandetanib—LTK—head—Parkinson's disease	0.000892	0.00579	CbGeAlD
Vandetanib—FGR—embryo—Parkinson's disease	0.000891	0.00578	CbGeAlD
Vandetanib—RET—embryo—Parkinson's disease	0.000891	0.00578	CbGeAlD
Vandetanib—FMO1—forebrain—Parkinson's disease	0.00088	0.00571	CbGeAlD
Vandetanib—EPHA8—head—Parkinson's disease	0.000855	0.00555	CbGeAlD
Vandetanib—Bosutinib—ABL1—Parkinson's disease	0.000854	0.0931	CrCbGaD
Vandetanib—ERBB3—forebrain—Parkinson's disease	0.000849	0.00551	CbGeAlD
Vandetanib—EPHA5—medulla oblongata—Parkinson's disease	0.000835	0.00541	CbGeAlD
Vandetanib—FLT3—cardiovascular system—Parkinson's disease	0.000831	0.00539	CbGeAlD
Vandetanib—FYN—embryo—Parkinson's disease	0.00083	0.00539	CbGeAlD
Vandetanib—ABL1—hindbrain—Parkinson's disease	0.000818	0.00531	CbGeAlD
Vandetanib—TEK—embryo—Parkinson's disease	0.000811	0.00526	CbGeAlD
Vandetanib—EPHA8—nervous system—Parkinson's disease	0.000811	0.00526	CbGeAlD
Vandetanib—EPHA8—central nervous system—Parkinson's disease	0.000781	0.00506	CbGeAlD
Vandetanib—EPHA8—cerebellum—Parkinson's disease	0.000763	0.00495	CbGeAlD
Vandetanib—EPHA5—midbrain—Parkinson's disease	0.000763	0.00495	CbGeAlD
Vandetanib—FYN—brainstem—Parkinson's disease	0.000761	0.00494	CbGeAlD
Vandetanib—FLT4—cardiovascular system—Parkinson's disease	0.000755	0.00489	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—Parkinson's disease	0.00075	0.00487	CbGeAlD
Vandetanib—EPHA5—spinal cord—Parkinson's disease	0.000744	0.00483	CbGeAlD
Vandetanib—TYRO3—spinal cord—Parkinson's disease	0.000744	0.00483	CbGeAlD
Vandetanib—FYN—forebrain—Parkinson's disease	0.000734	0.00476	CbGeAlD
Vandetanib—SRC—embryo—Parkinson's disease	0.000721	0.00468	CbGeAlD
Vandetanib—MAP4K5—forebrain—Parkinson's disease	0.000718	0.00465	CbGeAlD
Vandetanib—EPHA6—head—Parkinson's disease	0.000713	0.00463	CbGeAlD
Vandetanib—EPHB6—forebrain—Parkinson's disease	0.000686	0.00445	CbGeAlD
Vandetanib—EPHA6—nervous system—Parkinson's disease	0.000676	0.00439	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—Parkinson's disease	0.000674	0.00437	CbGeAlD
Vandetanib—FGR—cardiovascular system—Parkinson's disease	0.000666	0.00432	CbGeAlD
Vandetanib—AXL—cardiovascular system—Parkinson's disease	0.000664	0.0043	CbGeAlD
Vandetanib—KDR—embryo—Parkinson's disease	0.000663	0.0043	CbGeAlD
Vandetanib—TYRO3—head—Parkinson's disease	0.000662	0.00429	CbGeAlD
Vandetanib—EPHA5—head—Parkinson's disease	0.000662	0.00429	CbGeAlD
Vandetanib—LYN—head—Parkinson's disease	0.000658	0.00427	CbGeAlD
Vandetanib—EPHA6—central nervous system—Parkinson's disease	0.000651	0.00422	CbGeAlD
Vandetanib—BMPR1B—head—Parkinson's disease	0.000648	0.0042	CbGeAlD
Vandetanib—MAP3K19—head—Parkinson's disease	0.000648	0.0042	CbGeAlD
Vandetanib—LTK—brain—Parkinson's disease	0.000646	0.00419	CbGeAlD
Vandetanib—RIPK2—medulla oblongata—Parkinson's disease	0.000641	0.00416	CbGeAlD
Vandetanib—SRC—forebrain—Parkinson's disease	0.000638	0.00414	CbGeAlD
Vandetanib—STK35—midbrain—Parkinson's disease	0.000636	0.00412	CbGeAlD
Vandetanib—TYRO3—nervous system—Parkinson's disease	0.000627	0.00407	CbGeAlD
Vandetanib—EPHA5—nervous system—Parkinson's disease	0.000627	0.00407	CbGeAlD
Vandetanib—IRAK4—medulla oblongata—Parkinson's disease	0.000626	0.00406	CbGeAlD
Vandetanib—LYN—nervous system—Parkinson's disease	0.000624	0.00405	CbGeAlD
Vandetanib—FYN—cardiovascular system—Parkinson's disease	0.000621	0.00403	CbGeAlD
Vandetanib—EPHA8—brain—Parkinson's disease	0.00062	0.00402	CbGeAlD
Vandetanib—BMPR1B—nervous system—Parkinson's disease	0.000615	0.00399	CbGeAlD
Vandetanib—MAP3K19—nervous system—Parkinson's disease	0.000615	0.00399	CbGeAlD
Vandetanib—MAP2K5—brainstem—Parkinson's disease	0.000608	0.00394	CbGeAlD
Vandetanib—TEK—cardiovascular system—Parkinson's disease	0.000607	0.00394	CbGeAlD
Vandetanib—TYRO3—central nervous system—Parkinson's disease	0.000604	0.00392	CbGeAlD
Vandetanib—EPHA5—central nervous system—Parkinson's disease	0.000604	0.00392	CbGeAlD
Vandetanib—LYN—central nervous system—Parkinson's disease	0.000601	0.0039	CbGeAlD
Vandetanib—BMPR1B—central nervous system—Parkinson's disease	0.000592	0.00384	CbGeAlD
Vandetanib—MAP3K19—central nervous system—Parkinson's disease	0.000592	0.00384	CbGeAlD
Vandetanib—EPHA5—cerebellum—Parkinson's disease	0.00059	0.00383	CbGeAlD
Vandetanib—TYRO3—cerebellum—Parkinson's disease	0.00059	0.00383	CbGeAlD
Vandetanib—KDR—forebrain—Parkinson's disease	0.000587	0.0038	CbGeAlD
Vandetanib—RIPK2—midbrain—Parkinson's disease	0.000586	0.0038	CbGeAlD
Vandetanib—BMPR1B—cerebellum—Parkinson's disease	0.000578	0.00375	CbGeAlD
Vandetanib—MKNK1—medulla oblongata—Parkinson's disease	0.000576	0.00374	CbGeAlD
Vandetanib—PDGFRB—embryo—Parkinson's disease	0.000574	0.00372	CbGeAlD
Vandetanib—RIPK2—spinal cord—Parkinson's disease	0.000572	0.00371	CbGeAlD
Vandetanib—VEGFA—spinal cord—Parkinson's disease	0.00057	0.0037	CbGeAlD
Vandetanib—RET—medulla oblongata—Parkinson's disease	0.000569	0.00369	CbGeAlD
Vandetanib—AXL—medulla oblongata—Parkinson's disease	0.000567	0.00368	CbGeAlD
Vandetanib—ERBB3—midbrain—Parkinson's disease	0.000561	0.00364	CbGeAlD
Vandetanib—IRAK4—spinal cord—Parkinson's disease	0.000558	0.00362	CbGeAlD
Vandetanib—STK10—cardiovascular system—Parkinson's disease	0.000555	0.0036	CbGeAlD
Vandetanib—STK35—head—Parkinson's disease	0.000551	0.00357	CbGeAlD
Vandetanib—ERBB3—spinal cord—Parkinson's disease	0.000547	0.00355	CbGeAlD
Vandetanib—SLK—medulla oblongata—Parkinson's disease	0.000546	0.00354	CbGeAlD
Vandetanib—SRC—cardiovascular system—Parkinson's disease	0.000539	0.0035	CbGeAlD
Vandetanib—FYN—medulla oblongata—Parkinson's disease	0.000531	0.00344	CbGeAlD
Vandetanib—MKNK1—midbrain—Parkinson's disease	0.000527	0.00342	CbGeAlD
Vandetanib—STK35—nervous system—Parkinson's disease	0.000523	0.00339	CbGeAlD
Vandetanib—RET—midbrain—Parkinson's disease	0.00052	0.00337	CbGeAlD
Vandetanib—MAP4K5—medulla oblongata—Parkinson's disease	0.000519	0.00336	CbGeAlD
Vandetanib—TEK—medulla oblongata—Parkinson's disease	0.000519	0.00336	CbGeAlD
Vandetanib—AXL—midbrain—Parkinson's disease	0.000518	0.00336	CbGeAlD
Vandetanib—EPHA6—brain—Parkinson's disease	0.000517	0.00335	CbGeAlD
Vandetanib—MKNK1—spinal cord—Parkinson's disease	0.000514	0.00333	CbGeAlD
Vandetanib—ABL1—embryo—Parkinson's disease	0.000512	0.00332	CbGeAlD
Vandetanib—FLT4—head—Parkinson's disease	0.000511	0.00331	CbGeAlD
Vandetanib—PLK4—brain—Parkinson's disease	0.00051	0.00331	CbGeAlD
Vandetanib—RIPK2—head—Parkinson's disease	0.000508	0.0033	CbGeAlD
Vandetanib—RET—spinal cord—Parkinson's disease	0.000508	0.00329	CbGeAlD
Vandetanib—AXL—spinal cord—Parkinson's disease	0.000506	0.00328	CbGeAlD
Vandetanib—FMO1—head—Parkinson's disease	0.000504	0.00327	CbGeAlD
Vandetanib—STK35—central nervous system—Parkinson's disease	0.000503	0.00326	CbGeAlD
Vandetanib—FLT3—cerebellum—Parkinson's disease	0.000502	0.00326	CbGeAlD
Vandetanib—SLK—midbrain—Parkinson's disease	0.000499	0.00323	CbGeAlD
Vandetanib—IRAK4—head—Parkinson's disease	0.000496	0.00322	CbGeAlD
Vandetanib—KDR—cardiovascular system—Parkinson's disease	0.000496	0.00322	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—Parkinson's disease	0.000496	0.00322	CbGeAlD
Vandetanib—EPHB6—medulla oblongata—Parkinson's disease	0.000496	0.00321	CbGeAlD
Vandetanib—STK35—cerebellum—Parkinson's disease	0.000492	0.00319	CbGeAlD
Vandetanib—SLK—spinal cord—Parkinson's disease	0.000487	0.00316	CbGeAlD
Vandetanib—ERBB3—head—Parkinson's disease	0.000486	0.00315	CbGeAlD
Vandetanib—FYN—midbrain—Parkinson's disease	0.000485	0.00315	CbGeAlD
Vandetanib—EPHA5—brain—Parkinson's disease	0.000479	0.00311	CbGeAlD
Vandetanib—TYRO3—brain—Parkinson's disease	0.000479	0.00311	CbGeAlD
Vandetanib—ABL2—cerebellum—Parkinson's disease	0.000479	0.00311	CbGeAlD
Vandetanib—YES1—medulla oblongata—Parkinson's disease	0.000479	0.00311	CbGeAlD
Vandetanib—FMO1—nervous system—Parkinson's disease	0.000478	0.0031	CbGeAlD
Vandetanib—LYN—brain—Parkinson's disease	0.000477	0.00309	CbGeAlD
Vandetanib—MAP4K5—midbrain—Parkinson's disease	0.000474	0.00307	CbGeAlD
Vandetanib—TEK—midbrain—Parkinson's disease	0.000474	0.00307	CbGeAlD
Vandetanib—FYN—spinal cord—Parkinson's disease	0.000473	0.00307	CbGeAlD
Vandetanib—IRAK4—nervous system—Parkinson's disease	0.00047	0.00305	CbGeAlD
Vandetanib—MAP3K19—brain—Parkinson's disease	0.00047	0.00305	CbGeAlD
Vandetanib—BMPR1B—brain—Parkinson's disease	0.00047	0.00305	CbGeAlD
Vandetanib—ABL1—brainstem—Parkinson's disease	0.000469	0.00304	CbGeAlD
Vandetanib—EGFR—cerebellum—Parkinson's disease	0.000468	0.00303	CbGeAlD
Vandetanib—MAP4K5—spinal cord—Parkinson's disease	0.000462	0.003	CbGeAlD
Vandetanib—TEK—spinal cord—Parkinson's disease	0.000462	0.003	CbGeAlD
Vandetanib—ERBB3—nervous system—Parkinson's disease	0.000461	0.00299	CbGeAlD
Vandetanib—FMO1—central nervous system—Parkinson's disease	0.00046	0.00298	CbGeAlD
Vandetanib—MKNK1—head—Parkinson's disease	0.000457	0.00296	CbGeAlD
Vandetanib—RIPK2—cerebellum—Parkinson's disease	0.000453	0.00294	CbGeAlD
Vandetanib—IRAK4—central nervous system—Parkinson's disease	0.000453	0.00294	CbGeAlD
Vandetanib—EPHB6—midbrain—Parkinson's disease	0.000453	0.00294	CbGeAlD
Vandetanib—VEGFA—cerebellum—Parkinson's disease	0.000452	0.00293	CbGeAlD
Vandetanib—FGR—head—Parkinson's disease	0.000451	0.00293	CbGeAlD
Vandetanib—RET—head—Parkinson's disease	0.000451	0.00293	CbGeAlD
Vandetanib—AXL—head—Parkinson's disease	0.000449	0.00291	CbGeAlD
Vandetanib—ERBB3—central nervous system—Parkinson's disease	0.000444	0.00288	CbGeAlD
Vandetanib—IRAK4—cerebellum—Parkinson's disease	0.000443	0.00287	CbGeAlD
Vandetanib—EPHB6—spinal cord—Parkinson's disease	0.000442	0.00287	CbGeAlD
Vandetanib—YES1—midbrain—Parkinson's disease	0.000438	0.00284	CbGeAlD
Vandetanib—FMO3—head—Parkinson's disease	0.000436	0.00283	CbGeAlD
Vandetanib—ERBB3—cerebellum—Parkinson's disease	0.000434	0.00281	CbGeAlD
Vandetanib—MKNK1—nervous system—Parkinson's disease	0.000433	0.00281	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—Parkinson's disease	0.000429	0.00278	CbGeAlD
Vandetanib—FGR—nervous system—Parkinson's disease	0.000428	0.00277	CbGeAlD
Vandetanib—RET—nervous system—Parkinson's disease	0.000428	0.00277	CbGeAlD
Vandetanib—YES1—spinal cord—Parkinson's disease	0.000427	0.00277	CbGeAlD
Vandetanib—AXL—nervous system—Parkinson's disease	0.000426	0.00276	CbGeAlD
Vandetanib—KDR—medulla oblongata—Parkinson's disease	0.000424	0.00275	CbGeAlD
Vandetanib—MAP2K5—medulla oblongata—Parkinson's disease	0.000424	0.00275	CbGeAlD
Vandetanib—FYN—head—Parkinson's disease	0.000421	0.00273	CbGeAlD
Vandetanib—MKNK1—central nervous system—Parkinson's disease	0.000417	0.0027	CbGeAlD
Vandetanib—FMO3—nervous system—Parkinson's disease	0.000413	0.00268	CbGeAlD
Vandetanib—FGR—central nervous system—Parkinson's disease	0.000412	0.00267	CbGeAlD
Vandetanib—RET—central nervous system—Parkinson's disease	0.000412	0.00267	CbGeAlD
Vandetanib—TEK—head—Parkinson's disease	0.000411	0.00267	CbGeAlD
Vandetanib—MAP4K5—head—Parkinson's disease	0.000411	0.00267	CbGeAlD
Vandetanib—SRC—spinal cord—Parkinson's disease	0.000411	0.00266	CbGeAlD
Vandetanib—AXL—central nervous system—Parkinson's disease	0.00041	0.00266	CbGeAlD
Vandetanib—MKNK1—cerebellum—Parkinson's disease	0.000407	0.00264	CbGeAlD
Vandetanib—RET—cerebellum—Parkinson's disease	0.000402	0.00261	CbGeAlD
Vandetanib—AXL—cerebellum—Parkinson's disease	0.000401	0.0026	CbGeAlD
Vandetanib—STK35—brain—Parkinson's disease	0.000399	0.00259	CbGeAlD
Vandetanib—FYN—nervous system—Parkinson's disease	0.000399	0.00259	CbGeAlD
Vandetanib—FMO3—central nervous system—Parkinson's disease	0.000398	0.00258	CbGeAlD
Vandetanib—EPHB6—head—Parkinson's disease	0.000393	0.00255	CbGeAlD
Vandetanib—TEK—nervous system—Parkinson's disease	0.00039	0.00253	CbGeAlD
Vandetanib—MAP4K5—nervous system—Parkinson's disease	0.00039	0.00253	CbGeAlD
Vandetanib—ABL2—brain—Parkinson's disease	0.000389	0.00252	CbGeAlD
Vandetanib—MAP2K5—midbrain—Parkinson's disease	0.000387	0.00251	CbGeAlD
Vandetanib—KDR—midbrain—Parkinson's disease	0.000387	0.00251	CbGeAlD
Vandetanib—SLK—cerebellum—Parkinson's disease	0.000386	0.0025	CbGeAlD
Vandetanib—FYN—central nervous system—Parkinson's disease	0.000384	0.00249	CbGeAlD
Vandetanib—ABL1—cardiovascular system—Parkinson's disease	0.000383	0.00248	CbGeAlD
Vandetanib—EGFR—brain—Parkinson's disease	0.00038	0.00246	CbGeAlD
Vandetanib—YES1—head—Parkinson's disease	0.00038	0.00246	CbGeAlD
Vandetanib—MAP2K5—spinal cord—Parkinson's disease	0.000378	0.00245	CbGeAlD
Vandetanib—KDR—spinal cord—Parkinson's disease	0.000378	0.00245	CbGeAlD
Vandetanib—STK10—head—Parkinson's disease	0.000376	0.00244	CbGeAlD
Vandetanib—FYN—cerebellum—Parkinson's disease	0.000375	0.00243	CbGeAlD
Vandetanib—TEK—central nervous system—Parkinson's disease	0.000375	0.00243	CbGeAlD
Vandetanib—MAP4K5—central nervous system—Parkinson's disease	0.000375	0.00243	CbGeAlD
Vandetanib—EPHB6—nervous system—Parkinson's disease	0.000372	0.00241	CbGeAlD
Vandetanib—FLT4—brain—Parkinson's disease	0.00037	0.0024	CbGeAlD
Vandetanib—RIPK2—brain—Parkinson's disease	0.000368	0.00239	CbGeAlD
Vandetanib—VEGFA—brain—Parkinson's disease	0.000367	0.00238	CbGeAlD
Vandetanib—PDGFRB—medulla oblongata—Parkinson's disease	0.000367	0.00238	CbGeAlD
Vandetanib—TEK—cerebellum—Parkinson's disease	0.000367	0.00238	CbGeAlD
Vandetanib—MAP4K5—cerebellum—Parkinson's disease	0.000367	0.00238	CbGeAlD
Vandetanib—FMO1—brain—Parkinson's disease	0.000365	0.00237	CbGeAlD
Vandetanib—SRC—head—Parkinson's disease	0.000365	0.00237	CbGeAlD
Vandetanib—Afatinib—ABCB1—Parkinson's disease	0.000363	0.0396	CrCbGaD
Vandetanib—YES1—nervous system—Parkinson's disease	0.00036	0.00233	CbGeAlD
Vandetanib—IRAK4—brain—Parkinson's disease	0.00036	0.00233	CbGeAlD
Vandetanib—Erlotinib—CYP2D6—Parkinson's disease	0.000359	0.0391	CrCbGaD
Vandetanib—EPHB6—central nervous system—Parkinson's disease	0.000358	0.00232	CbGeAlD
Vandetanib—STK10—nervous system—Parkinson's disease	0.000357	0.00231	CbGeAlD
Vandetanib—ERBB3—brain—Parkinson's disease	0.000352	0.00229	CbGeAlD
Vandetanib—EPHB6—cerebellum—Parkinson's disease	0.00035	0.00227	CbGeAlD
Vandetanib—YES1—central nervous system—Parkinson's disease	0.000346	0.00225	CbGeAlD
Vandetanib—SRC—nervous system—Parkinson's disease	0.000346	0.00224	CbGeAlD
Vandetanib—STK10—central nervous system—Parkinson's disease	0.000343	0.00223	CbGeAlD
Vandetanib—YES1—cerebellum—Parkinson's disease	0.000339	0.0022	CbGeAlD
Vandetanib—KDR—head—Parkinson's disease	0.000336	0.00218	CbGeAlD
Vandetanib—MAP2K5—head—Parkinson's disease	0.000336	0.00218	CbGeAlD
Vandetanib—STK10—cerebellum—Parkinson's disease	0.000336	0.00218	CbGeAlD
Vandetanib—PDGFRB—midbrain—Parkinson's disease	0.000335	0.00217	CbGeAlD
Vandetanib—SRC—central nervous system—Parkinson's disease	0.000333	0.00216	CbGeAlD
Vandetanib—MKNK1—brain—Parkinson's disease	0.000331	0.00215	CbGeAlD
Vandetanib—PDGFRB—spinal cord—Parkinson's disease	0.000327	0.00212	CbGeAlD
Vandetanib—ABL1—medulla oblongata—Parkinson's disease	0.000327	0.00212	CbGeAlD
Vandetanib—FGR—brain—Parkinson's disease	0.000327	0.00212	CbGeAlD
Vandetanib—RET—brain—Parkinson's disease	0.000327	0.00212	CbGeAlD
Vandetanib—SRC—cerebellum—Parkinson's disease	0.000326	0.00211	CbGeAlD
Vandetanib—AXL—brain—Parkinson's disease	0.000326	0.00211	CbGeAlD
Vandetanib—KDR—nervous system—Parkinson's disease	0.000318	0.00207	CbGeAlD
Vandetanib—MAP2K5—nervous system—Parkinson's disease	0.000318	0.00207	CbGeAlD
Vandetanib—FMO3—brain—Parkinson's disease	0.000316	0.00205	CbGeAlD
Vandetanib—SLK—brain—Parkinson's disease	0.000313	0.00203	CbGeAlD
Vandetanib—ORM1—spinal cord—Parkinson's disease	0.000307	0.00199	CbGeAlD
Vandetanib—MAP2K5—central nervous system—Parkinson's disease	0.000307	0.00199	CbGeAlD
Vandetanib—KDR—central nervous system—Parkinson's disease	0.000307	0.00199	CbGeAlD
Vandetanib—FYN—brain—Parkinson's disease	0.000305	0.00198	CbGeAlD
Vandetanib—KDR—cerebellum—Parkinson's disease	0.0003	0.00194	CbGeAlD
Vandetanib—MAP2K5—cerebellum—Parkinson's disease	0.0003	0.00194	CbGeAlD
Vandetanib—ABL1—midbrain—Parkinson's disease	0.000299	0.00194	CbGeAlD
Vandetanib—MAP4K5—brain—Parkinson's disease	0.000298	0.00193	CbGeAlD
Vandetanib—TEK—brain—Parkinson's disease	0.000298	0.00193	CbGeAlD
Vandetanib—ABL1—spinal cord—Parkinson's disease	0.000292	0.00189	CbGeAlD
Vandetanib—PDGFRB—head—Parkinson's disease	0.000291	0.00189	CbGeAlD
Vandetanib—EPHB6—brain—Parkinson's disease	0.000285	0.00185	CbGeAlD
Vandetanib—PDGFRB—nervous system—Parkinson's disease	0.000276	0.00179	CbGeAlD
Vandetanib—YES1—brain—Parkinson's disease	0.000275	0.00178	CbGeAlD
Vandetanib—STK10—brain—Parkinson's disease	0.000273	0.00177	CbGeAlD
Vandetanib—PDGFRB—central nervous system—Parkinson's disease	0.000265	0.00172	CbGeAlD
Vandetanib—SRC—brain—Parkinson's disease	0.000265	0.00172	CbGeAlD
Vandetanib—PDGFRB—cerebellum—Parkinson's disease	0.000259	0.00168	CbGeAlD
Vandetanib—ABL1—head—Parkinson's disease	0.000259	0.00168	CbGeAlD
Vandetanib—ORM1—nervous system—Parkinson's disease	0.000259	0.00168	CbGeAlD
Vandetanib—Erlotinib—ABCB1—Parkinson's disease	0.000256	0.0279	CrCbGaD
Vandetanib—ORM1—central nervous system—Parkinson's disease	0.000249	0.00161	CbGeAlD
Vandetanib—ABL1—nervous system—Parkinson's disease	0.000246	0.00159	CbGeAlD
Vandetanib—KDR—brain—Parkinson's disease	0.000243	0.00158	CbGeAlD
Vandetanib—MAP2K5—brain—Parkinson's disease	0.000243	0.00158	CbGeAlD
Vandetanib—ABL1—central nervous system—Parkinson's disease	0.000236	0.00153	CbGeAlD
Vandetanib—ABL1—cerebellum—Parkinson's disease	0.000231	0.0015	CbGeAlD
Vandetanib—Gefitinib—CYP2D6—Parkinson's disease	0.000225	0.0245	CrCbGaD
Vandetanib—PDGFRB—brain—Parkinson's disease	0.000211	0.00137	CbGeAlD
Vandetanib—ABCG2—medulla oblongata—Parkinson's disease	0.000206	0.00134	CbGeAlD
Vandetanib—ABCG2—midbrain—Parkinson's disease	0.000188	0.00122	CbGeAlD
Vandetanib—ABL1—brain—Parkinson's disease	0.000188	0.00122	CbGeAlD
Vandetanib—ABCG2—spinal cord—Parkinson's disease	0.000184	0.00119	CbGeAlD
Vandetanib—ABCC1—cerebellum—Parkinson's disease	0.000176	0.00114	CbGeAlD
Vandetanib—ALB—brain—Parkinson's disease	0.000173	0.00112	CbGeAlD
Vandetanib—Gefitinib—ABCB1—Parkinson's disease	0.00016	0.0175	CrCbGaD
Vandetanib—Bosutinib—ABCB1—Parkinson's disease	0.000158	0.0172	CrCbGaD
Vandetanib—ABCG2—cerebellum—Parkinson's disease	0.000146	0.000945	CbGeAlD
Vandetanib—ABCC1—brain—Parkinson's disease	0.000143	0.000928	CbGeAlD
Vandetanib—ABCG2—brain—Parkinson's disease	0.000118	0.000768	CbGeAlD
Vandetanib—CYP3A4—nervous system—Parkinson's disease	0.000108	0.0007	CbGeAlD
Vandetanib—CYP3A4—central nervous system—Parkinson's disease	0.000104	0.000674	CbGeAlD
Vandetanib—ABCC1—Metabolism—COMT—Parkinson's disease	7.01e-06	2.92e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GSTP1—Parkinson's disease	6.98e-06	2.91e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CYCS—Parkinson's disease	6.97e-06	2.91e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—IL6—Parkinson's disease	6.97e-06	2.9e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—MAOA—Parkinson's disease	6.97e-06	2.9e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	6.95e-06	2.9e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—HMOX1—Parkinson's disease	6.89e-06	2.87e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—APOE—Parkinson's disease	6.88e-06	2.87e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INSR—Parkinson's disease	6.85e-06	2.86e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PLA2G6—Parkinson's disease	6.83e-06	2.85e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD3—Parkinson's disease	6.81e-06	2.84e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—Parkinson's disease	6.8e-06	2.84e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—IL6—Parkinson's disease	6.79e-06	2.83e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—APOE—Parkinson's disease	6.79e-06	2.83e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—Parkinson's disease	6.77e-06	2.82e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MTHFR—Parkinson's disease	6.77e-06	2.82e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MAOB—Parkinson's disease	6.76e-06	2.82e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—MAPK8—Parkinson's disease	6.76e-06	2.82e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—IL6—Parkinson's disease	6.72e-06	2.8e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—Parkinson's disease	6.7e-06	2.79e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—HGF—Parkinson's disease	6.67e-06	2.78e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCH1—Parkinson's disease	6.63e-06	2.76e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—INS—Parkinson's disease	6.62e-06	2.76e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ABCB1—Parkinson's disease	6.61e-06	2.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADRBK1—Parkinson's disease	6.6e-06	2.75e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—APOE—Parkinson's disease	6.56e-06	2.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—IL6—Parkinson's disease	6.54e-06	2.73e-05	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—IL6—Parkinson's disease	6.5e-06	2.71e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGB—Parkinson's disease	6.48e-06	2.7e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1B—Parkinson's disease	6.47e-06	2.7e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—MAPK8—Parkinson's disease	6.46e-06	2.69e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—INS—Parkinson's disease	6.45e-06	2.69e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR1A—Parkinson's disease	6.44e-06	2.69e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	6.44e-06	2.68e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF2—Parkinson's disease	6.43e-06	2.68e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GSTM1—Parkinson's disease	6.42e-06	2.67e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD2—Parkinson's disease	6.39e-06	2.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR7—Parkinson's disease	6.39e-06	2.66e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—INS—Parkinson's disease	6.38e-06	2.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MTHFR—Parkinson's disease	6.38e-06	2.66e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADRBK1—Parkinson's disease	6.36e-06	2.65e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TAC1—Parkinson's disease	6.35e-06	2.65e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—APOE—Parkinson's disease	6.3e-06	2.63e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF2—Parkinson's disease	6.3e-06	2.62e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—MAPK8—Parkinson's disease	6.22e-06	2.59e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD1—Parkinson's disease	6.22e-06	2.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1R—Parkinson's disease	6.22e-06	2.59e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—IL6—Parkinson's disease	6.21e-06	2.59e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF2—Parkinson's disease	6.2e-06	2.58e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—COMT—Parkinson's disease	6.17e-06	2.57e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—IL6—Parkinson's disease	6.17e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR7—Parkinson's disease	6.16e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD2—Parkinson's disease	6.16e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MTHFR—Parkinson's disease	6.15e-06	2.56e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GPX1—Parkinson's disease	6.14e-06	2.56e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GSTP1—Parkinson's disease	6.14e-06	2.56e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EDN1—Parkinson's disease	6.14e-06	2.56e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MAOA—Parkinson's disease	6.13e-06	2.56e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—INS—Parkinson's disease	6.09e-06	2.54e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1R—Parkinson's disease	6.09e-06	2.54e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—HMOX1—Parkinson's disease	6.06e-06	2.53e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD3—Parkinson's disease	6.03e-06	2.51e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EDN1—Parkinson's disease	6.01e-06	2.51e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1R—Parkinson's disease	5.99e-06	2.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—APOE—Parkinson's disease	5.94e-06	2.48e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—MAPK8—Parkinson's disease	5.93e-06	2.47e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EDN1—Parkinson's disease	5.92e-06	2.47e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GBA—Parkinson's disease	5.91e-06	2.46e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FBP1—Parkinson's disease	5.91e-06	2.46e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DBH—Parkinson's disease	5.91e-06	2.46e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—INS—Parkinson's disease	5.87e-06	2.45e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ABCB1—Parkinson's disease	5.82e-06	2.42e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—INS—Parkinson's disease	5.8e-06	2.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—Parkinson's disease	5.79e-06	2.41e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—APOE—Parkinson's disease	5.73e-06	2.39e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—Parkinson's disease	5.68e-06	2.37e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—MTHFR—Parkinson's disease	5.67e-06	2.36e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GSTM1—Parkinson's disease	5.65e-06	2.35e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NGF—Parkinson's disease	5.65e-06	2.35e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADRBK1—Parkinson's disease	5.63e-06	2.35e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—INS—Parkinson's disease	5.6e-06	2.34e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—Parkinson's disease	5.58e-06	2.33e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NGF—Parkinson's disease	5.53e-06	2.3e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—MAPK8—Parkinson's disease	5.51e-06	2.3e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—Parkinson's disease	5.49e-06	2.29e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—Parkinson's disease	5.46e-06	2.28e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD2—Parkinson's disease	5.45e-06	2.27e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR7—Parkinson's disease	5.45e-06	2.27e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MTHFR—Parkinson's disease	5.44e-06	2.27e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NGF—Parkinson's disease	5.44e-06	2.27e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—Parkinson's disease	5.41e-06	2.26e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GPX1—Parkinson's disease	5.41e-06	2.25e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—Parkinson's disease	5.41e-06	2.25e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CASP3—Parkinson's disease	5.39e-06	2.25e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—INS—Parkinson's disease	5.38e-06	2.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HTR2A—Parkinson's disease	5.37e-06	2.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF2—Parkinson's disease	5.35e-06	2.23e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—APOE—Parkinson's disease	5.28e-06	2.2e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HTR2A—Parkinson's disease	5.26e-06	2.19e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HTR2A—Parkinson's disease	5.18e-06	2.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1R—Parkinson's disease	5.18e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF2—Parkinson's disease	5.16e-06	2.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EDN1—Parkinson's disease	5.12e-06	2.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—INS—Parkinson's disease	5.08e-06	2.12e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—APOE—Parkinson's disease	5.07e-06	2.11e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP2D6—Parkinson's disease	5.03e-06	2.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—APOE—Parkinson's disease	5e-06	2.08e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MTHFR—Parkinson's disease	4.99e-06	2.08e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1R—Parkinson's disease	4.99e-06	2.08e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MAPK8—Parkinson's disease	4.96e-06	2.07e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—Parkinson's disease	4.95e-06	2.06e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—Parkinson's disease	4.94e-06	2.06e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CTGF—Parkinson's disease	4.93e-06	2.06e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CASP3—Parkinson's disease	4.93e-06	2.06e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EDN1—Parkinson's disease	4.93e-06	2.06e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1B—Parkinson's disease	4.93e-06	2.05e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—Parkinson's disease	4.89e-06	2.04e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—APOE—Parkinson's disease	4.89e-06	2.04e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—INS—Parkinson's disease	4.89e-06	2.04e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—Parkinson's disease	4.85e-06	2.02e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—Parkinson's disease	4.83e-06	2.01e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1B—Parkinson's disease	4.82e-06	2.01e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—APOE—Parkinson's disease	4.82e-06	2.01e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CASP3—Parkinson's disease	4.81e-06	2e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1B—Parkinson's disease	4.8e-06	2e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—Parkinson's disease	4.77e-06	1.99e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CASP3—Parkinson's disease	4.75e-06	1.98e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1B—Parkinson's disease	4.75e-06	1.98e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—Parkinson's disease	4.71e-06	1.96e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—Parkinson's disease	4.71e-06	1.96e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NGF—Parkinson's disease	4.7e-06	1.96e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—Parkinson's disease	4.69e-06	1.96e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—Parkinson's disease	4.67e-06	1.95e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—APOE—Parkinson's disease	4.64e-06	1.94e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP2E1—Parkinson's disease	4.6e-06	1.92e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF2—Parkinson's disease	4.57e-06	1.9e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NQO1—Parkinson's disease	4.55e-06	1.89e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MAPK8—Parkinson's disease	4.53e-06	1.89e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NGF—Parkinson's disease	4.53e-06	1.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—MAPK8—Parkinson's disease	4.52e-06	1.88e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—INS—Parkinson's disease	4.51e-06	1.88e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TH—Parkinson's disease	4.48e-06	1.87e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR2A—Parkinson's disease	4.48e-06	1.87e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—MAPK8—Parkinson's disease	4.42e-06	1.84e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MAPK8—Parkinson's disease	4.42e-06	1.84e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1R—Parkinson's disease	4.42e-06	1.84e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—MAPK8—Parkinson's disease	4.4e-06	1.84e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MAPK8—Parkinson's disease	4.37e-06	1.82e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EDN1—Parkinson's disease	4.36e-06	1.82e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—MAPK8—Parkinson's disease	4.35e-06	1.82e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DDC—Parkinson's disease	4.34e-06	1.81e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—INS—Parkinson's disease	4.33e-06	1.81e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CASP3—Parkinson's disease	4.32e-06	1.8e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—Parkinson's disease	4.31e-06	1.8e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR2A—Parkinson's disease	4.31e-06	1.8e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYCS—Parkinson's disease	4.3e-06	1.79e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—INS—Parkinson's disease	4.27e-06	1.78e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—INS—Parkinson's disease	4.18e-06	1.74e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CASP3—Parkinson's disease	4.17e-06	1.74e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—APOE—Parkinson's disease	4.16e-06	1.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—Parkinson's disease	4.12e-06	1.72e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—INS—Parkinson's disease	4.11e-06	1.71e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—Parkinson's disease	4.1e-06	1.71e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTA4—Parkinson's disease	4.1e-06	1.71e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NGF—Parkinson's disease	4.01e-06	1.67e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—APOE—Parkinson's disease	4.01e-06	1.67e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—Parkinson's disease	3.98e-06	1.66e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—Parkinson's disease	3.98e-06	1.66e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—Parkinson's disease	3.97e-06	1.66e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MAPK8—Parkinson's disease	3.97e-06	1.65e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—INS—Parkinson's disease	3.97e-06	1.65e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—Parkinson's disease	3.95e-06	1.65e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MAPK8—Parkinson's disease	3.83e-06	1.6e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR2A—Parkinson's disease	3.82e-06	1.59e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—COMT—Parkinson's disease	3.81e-06	1.59e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTP1—Parkinson's disease	3.79e-06	1.58e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—Parkinson's disease	3.79e-06	1.58e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MAOA—Parkinson's disease	3.78e-06	1.58e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MAPK8—Parkinson's disease	3.76e-06	1.57e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HMOX1—Parkinson's disease	3.74e-06	1.56e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	3.69e-06	1.54e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MAOB—Parkinson's disease	3.65e-06	1.52e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—MAPK8—Parkinson's disease	3.62e-06	1.51e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—ABCB1—Parkinson's disease	3.59e-06	1.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—INS—Parkinson's disease	3.55e-06	1.48e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—APOE—Parkinson's disease	3.55e-06	1.48e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—Parkinson's disease	3.52e-06	1.47e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—Parkinson's disease	3.5e-06	1.46e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GSTM1—Parkinson's disease	3.48e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—INS—Parkinson's disease	3.43e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—Parkinson's disease	3.34e-06	1.39e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK8—Parkinson's disease	3.21e-06	1.34e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CASP3—Parkinson's disease	3.18e-06	1.32e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—Parkinson's disease	3.16e-06	1.32e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CASP3—Parkinson's disease	3.11e-06	1.3e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—Parkinson's disease	3.08e-06	1.28e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—Parkinson's disease	3.06e-06	1.28e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—Parkinson's disease	3.03e-06	1.26e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—Parkinson's disease	2.92e-06	1.22e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—Parkinson's disease	2.89e-06	1.21e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—Parkinson's disease	2.88e-06	1.2e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—Parkinson's disease	2.87e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—Parkinson's disease	2.86e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—Parkinson's disease	2.82e-06	1.18e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—Parkinson's disease	2.82e-06	1.18e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—Parkinson's disease	2.82e-06	1.17e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—Parkinson's disease	2.81e-06	1.17e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—Parkinson's disease	2.79e-06	1.16e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—Parkinson's disease	2.78e-06	1.16e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	2.71e-06	1.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—Parkinson's disease	2.66e-06	1.11e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CTGF—Parkinson's disease	2.66e-06	1.11e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—Parkinson's disease	2.65e-06	1.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—Parkinson's disease	2.63e-06	1.1e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—Parkinson's disease	2.57e-06	1.07e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—Parkinson's disease	2.55e-06	1.06e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—Parkinson's disease	2.54e-06	1.06e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	2.48e-06	1.03e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—Parkinson's disease	2.45e-06	1.02e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—Parkinson's disease	2.45e-06	1.02e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—Parkinson's disease	2.45e-06	1.02e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—Parkinson's disease	2.43e-06	1.01e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TH—Parkinson's disease	2.42e-06	1.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—Parkinson's disease	2.4e-06	1e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—Parkinson's disease	2.35e-06	9.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—Parkinson's disease	2.34e-06	9.77e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYCS—Parkinson's disease	2.32e-06	9.68e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—Parkinson's disease	2.31e-06	9.65e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—Parkinson's disease	2.26e-06	9.41e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—Parkinson's disease	2.22e-06	9.25e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—Parkinson's disease	2.14e-06	8.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—Parkinson's disease	2.07e-06	8.65e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COMT—Parkinson's disease	2.06e-06	8.57e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—Parkinson's disease	2.05e-06	8.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—Parkinson's disease	2.05e-06	8.53e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MAOA—Parkinson's disease	2.04e-06	8.51e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—Parkinson's disease	2.02e-06	8.41e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—Parkinson's disease	1.94e-06	8.08e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—Parkinson's disease	1.89e-06	7.89e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—Parkinson's disease	1.88e-06	7.84e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—Parkinson's disease	1.86e-06	7.77e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—Parkinson's disease	1.83e-06	7.61e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—Parkinson's disease	1.8e-06	7.51e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—Parkinson's disease	1.8e-06	7.49e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—Parkinson's disease	1.66e-06	6.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—Parkinson's disease	1.55e-06	6.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—Parkinson's disease	1.55e-06	6.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—Parkinson's disease	1.5e-06	6.24e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—Parkinson's disease	1.32e-06	5.52e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—Parkinson's disease	1.32e-06	5.51e-06	CbGpPWpGaD
